We are live on ! Find out more
KLRS icon

Kalaris Therapeutics

94 hedge funds and large institutions have $184M invested in Kalaris Therapeutics in 2023 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 47 increasing their positions, 18 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,800% more capital inflows, than outflows

Capital inflows: $62.9M | Capital outflows: $3.31M

161% more repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 18

60% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 10

7% more funds holding

Funds holding: 88 → 94 (+6)

5.17% more ownership

Funds ownership: 42.35% → 47.52% (+5.2%)

22% less call options, than puts

Call options by funds: $172K | Put options by funds: $221K

Holders
94
Holders Change
+6
Holders Change %
+6.82%
% of All Funds
1.47%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
16
Increased
47
Reduced
18
Closed
10
Calls
$172​K
Puts
$221​K
Net Calls
-⁠$49​K
Net Calls Change
-⁠$233​K

KLRS Hedge Fund Activity: Q2 2023 in Review

94 of the 6,391 institutional investors tracked by Wall St. Rank reported a position in Kalaris Therapeutics (KLRS) for Q2 2023, worth a combined $184M — up 18% from $156M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new KLRS positions and 10 closed out — a net gain of 6 holders — while 47 added to existing stakes and 18 trimmed.

The largest buyer was Wasatch Advisors, adding an estimated $22.3M. The largest seller was Vanguard Group, cutting an estimated $1.16M.

  • 94 institutional investors held Kalaris Therapeutics (KLRS) as of Q2 2023, up from 88 in Q1 2023.
  • Funds reported $184M of Kalaris Therapeutics stock for Q2 2023, up 18% quarter-over-quarter.
  • 16 funds opened new Kalaris Therapeutics positions in Q2 2023 and 10 closed out, a net change of +6 holders.
  • The largest Kalaris Therapeutics buyer in Q2 2023 was Wasatch Advisors, an estimated $22.3M added.
  • The largest Kalaris Therapeutics seller in Q2 2023 was Vanguard Group, an estimated $1.16M sold.

Based on aggregated 13F filings for Q2 2023.